Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib

被引：0
作者：
Katsuhiro Masago
Yosuke Togashi
Shiro Fujita
Yuichi Sakamori
Chiyuki Okuda
Young Hak Kim
Tadashi Mio
Michiaki Mishima
机构：
[1] Graduate School of Medicine,Department of Respiratory Medicine
[2] Kyoto University,Division of Integrated Oncology
[3] Institute of Biomedical Research and Innovation,undefined
来源：
Medical Oncology | 2012年 / 29卷
关键词：
Epidermal growth factor receptor; Gefitinib; Hepatocyte growth factor; Non-small cell lung cancer; Somatic mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese patients with advanced non-squamous NSCLC. The peptic nucleic acid-locked nucleic acid clamp method was used to determine their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and risk factors associated with prognosis. HGF-positive serum status (hazard ratio, 1.536; 95% confidence interval, 1.042–2.400; P = 0.0295) had a significant and independent negative effect on progression-free survival among patients with wild-type EGFR. We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR.
引用
收藏
页码：1614 / 1621
页数：7
相关论文
共 356 条
[1]  
Chou TY(2005)Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer Clin Cancer Res 11 3750-3757
[2]  
Chiu CH(2004)High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan Clin Cancer Res 10 8195-8203
[3]  
Li LH(2005)Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 339-346
[4]  
Hsiao CY(2005)The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers Clin Cancer Res 11 1167-1173
[5]  
Tzen CY(2003)Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) J Clin Oncol 21 2237-2246
[6]  
Chang KT(2005)Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol 23 8081-8092
[7]  
Chen YM(2006)Clinical experience with gefitinib: an update Crit Rev Oncol Hematol 58 31-45
[8]  
Perng RP(2005)Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients Ann Oncol 16 1081-1086
[9]  
Tsai SF(2005)Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study J Clin Oncol 23 6838-6845
[10]  
Tsai CM(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139
12345678910